ES2503794T3 - Inhibidores de la actividad Akt - Google Patents

Inhibidores de la actividad Akt Download PDF

Info

Publication number
ES2503794T3
ES2503794T3 ES10800980.4T ES10800980T ES2503794T3 ES 2503794 T3 ES2503794 T3 ES 2503794T3 ES 10800980 T ES10800980 T ES 10800980T ES 2503794 T3 ES2503794 T3 ES 2503794T3
Authority
ES
Spain
Prior art keywords
alkyl
independently selected
heterocycle
nitrogen
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10800980.4T
Other languages
English (en)
Spanish (es)
Inventor
Lixin Zhang
Graham Peter Trevitt
Hughes Miel
Frank Burkamp
Timothy Harrison
Andrew John Wilkinson
Charles-Henry Fabritius
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almac Discovery Ltd
Original Assignee
Almac Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Discovery Ltd filed Critical Almac Discovery Ltd
Application granted granted Critical
Publication of ES2503794T3 publication Critical patent/ES2503794T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES10800980.4T 2009-12-23 2010-12-23 Inhibidores de la actividad Akt Active ES2503794T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0922589 2009-12-23
GBGB0922589.7A GB0922589D0 (en) 2009-12-23 2009-12-23 Pharmaceutical compounds
PCT/GB2010/002329 WO2011077098A1 (en) 2009-12-23 2010-12-23 Inhibitors of akt activity

Publications (1)

Publication Number Publication Date
ES2503794T3 true ES2503794T3 (es) 2014-10-07

Family

ID=41716932

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10800980.4T Active ES2503794T3 (es) 2009-12-23 2010-12-23 Inhibidores de la actividad Akt

Country Status (21)

Country Link
US (1) US9221838B2 (https=)
EP (1) EP2516435B8 (https=)
JP (1) JP5923043B2 (https=)
KR (1) KR20140015157A (https=)
CN (1) CN102791708B (https=)
AU (1) AU2010334591C1 (https=)
BR (1) BR112012015677A2 (https=)
CA (1) CA2783340C (https=)
CY (1) CY1115686T1 (https=)
DK (1) DK2516435T3 (https=)
ES (1) ES2503794T3 (https=)
GB (1) GB0922589D0 (https=)
IL (1) IL220153A (https=)
MX (1) MX2012007274A (https=)
NZ (1) NZ600453A (https=)
PL (1) PL2516435T3 (https=)
PT (1) PT2516435E (https=)
RU (1) RU2579513C2 (https=)
SG (1) SG181517A1 (https=)
SI (1) SI2516435T1 (https=)
WO (1) WO2011077098A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201205164D0 (en) * 2012-03-23 2012-05-09 Almac Discovery Ltd Pharmaceutical compounds
JP6787899B2 (ja) * 2014-12-23 2020-11-18 ベルゲンビオ アーエスアー 医薬的活性化合物
US10323044B2 (en) * 2015-02-27 2019-06-18 Taiho Pharmaceutical Co., Ltd. Crystal of imidazo-oxazine, pharmaceutical composition containing said crystal, and method for producing said crystal
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
MA45865A (fr) * 2016-08-07 2021-04-14 Wistar Inst Procédés de détection et de traitement d'une tumeur exprimant pt346 pdk1
UA125730C2 (uk) * 2017-06-22 2022-05-25 Курадев Фарма Лімітед Низькомолекулярні модулятори sting людини
MX2020002611A (es) 2017-09-07 2020-07-13 Univ Res Inst Inc Augusta Activador especifico de akt3 y usos del mismo.
GB2600384A (en) * 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
WO2025250545A1 (en) * 2024-05-28 2025-12-04 Alterome Therapeutics, Inc. Akt1 modulators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL181893B1 (pl) * 1994-11-14 2001-10-31 Warner Lambert Co Zwiazki bedace pochodnymi pirymidyny i naftyrydyny oraz preparat farmaceutyczny zawierajacy je PL PL PL
TWI301760B (en) * 2004-02-27 2008-10-11 Merz Pharma Gmbh & Co Kgaa Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
US7910561B2 (en) * 2004-12-15 2011-03-22 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
EP1898903B8 (en) * 2005-06-10 2013-05-15 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2008011032A1 (en) * 2006-07-17 2008-01-24 Amgen Inc. Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
JP2010512312A (ja) 2006-12-06 2010-04-22 メルク エンド カムパニー インコーポレーテッド Akt活性の阻害剤
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
US7999107B2 (en) * 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
JP2011522048A (ja) * 2008-06-03 2011-07-28 メルク・シャープ・エンド・ドーム・コーポレイション Akt活性の阻害剤
US8536193B2 (en) 2008-06-03 2013-09-17 Merck Sharp & Dohme Corp. Inhibitors of AKT activity

Also Published As

Publication number Publication date
JP5923043B2 (ja) 2016-05-24
SI2516435T1 (sl) 2014-12-31
RU2579513C2 (ru) 2016-04-10
PL2516435T3 (pl) 2015-01-30
KR20140015157A (ko) 2014-02-06
MX2012007274A (es) 2012-10-03
AU2010334591B2 (en) 2014-04-10
GB0922589D0 (en) 2010-02-10
EP2516435B8 (en) 2014-10-15
AU2010334591C1 (en) 2014-07-31
IL220153A0 (en) 2012-07-31
BR112012015677A2 (pt) 2015-06-30
DK2516435T3 (da) 2014-10-13
EP2516435A1 (en) 2012-10-31
US9221838B2 (en) 2015-12-29
RU2012131115A (ru) 2014-01-27
HK1171013A1 (en) 2013-03-15
JP2013515710A (ja) 2013-05-09
US20130116243A1 (en) 2013-05-09
EP2516435B1 (en) 2014-08-06
CN102791708A (zh) 2012-11-21
IL220153A (en) 2015-05-31
NZ600453A (en) 2013-10-25
CA2783340C (en) 2015-11-24
CA2783340A1 (en) 2011-06-30
WO2011077098A1 (en) 2011-06-30
CY1115686T1 (el) 2017-01-25
WO2011077098A9 (en) 2012-04-19
CN102791708B (zh) 2016-03-02
AU2010334591A1 (en) 2012-06-21
PT2516435E (pt) 2014-11-13
SG181517A1 (en) 2012-07-30

Similar Documents

Publication Publication Date Title
ES2503794T3 (es) Inhibidores de la actividad Akt
ES2684268T3 (es) Inhibidores de pirimidinil tirosina quinasa
ES2604761T3 (es) Procesos para producir determinados 2-(piridina-3-il)tiazoles
ES2750236T3 (es) Derivados heteroaromáticos bicíclicos condensados como moduladores de la actividad del TNF
CA2480317A1 (en) 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
CN103649082A (zh) 吡啶衍生物和含有该吡啶衍生物的bace1抑制剂
ES2923278T3 (es) Intermedios útiles para la síntesis de derivados de aminopirimidinas, proceso de preparación del mismo y proceso de preparación de aminopirimidina derivados utilizando los mismos
CA2941663C (en) Piperidine derivatives as orexin receptor antagonist
ES2622754T3 (es) Acoplamiento catalizado por Pd de pirazol amidas
EP2825538B1 (en) Positive allosteric modulators of mglur2
MD3658552T2 (ro) Procedeu de obținere a N-(5-((4-(4-((dimetilamino)metil)-3-fenil-1H-pirazol-1-il)pirimidin-2-il)amino)-4-metoxi-2-morfolinofenil)acrilamidei prin prin reacţia aminei corespunzătoare cu clorură de 3-halo-propionil
ES2617241T3 (es) Derivados de triazol fusionados como moduladores de gama secretasa
CA2889466A1 (en) Novel process for making compounds for use in the treatment of cancer
CN101600716A (zh) 用于制备9-羟基-3-(2-氯乙基)-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮盐酸盐的改进方法
ES3010145T3 (en) Method of producing tetracyclic compound
WO2011109932A1 (en) Novel process for the manufacture of 5-halogenated-7-azaindoles
JP5697685B2 (ja) 三環式抗生物質
ES2650921T3 (es) Compuestos tricíclicos de imidazol como inhibidores de hidroxilasa de triptófano
ES2553387T3 (es) Compuestos heterocíclicos para el tratamiento o la prevención de trastornos causados por neurotransmisión reducida de serotonina, norepinefrina o dopamina
WO2017094026A1 (en) 3-pyrimidinyl pyrrolo [2,3-b] pyridine as new anticancer agents and the process for the preparation thereof
JP6573615B2 (ja) ピラゾール誘導体の製造方法
EP4543892A1 (en) Fluorescent probes for magl
JPWO2019059344A1 (ja) 化学活性化型水溶性プロドラッグ
CN102627657B (zh) 3-(4-甲氧基-苄基)-1h-嘧啶-2,4-二酮衍生物的合成方法
CN103739606B (zh) 2-氨基-5,8-二取代[1,2,4]三唑[1,5-c]嘧啶的环保合成方法